Table 1.
Baseline clinical features of 126 patients affected by thymic epithelial tumours (TET) vaccinated against SARS-CoV-2.
| Thymoma | Thymic carcinomaa | ||
|---|---|---|---|
| Gender | |||
| Female | 59 | 43 | 16 |
| Male | 67 | 41 | 26 |
| Median age (range) | 61 (21–89) | 59 (21–89) | 63 (42–81) |
| Comorbidities | |||
| Hypertension | 40 | 24 | 16 |
| Diabetes | 5 | 5 | 0 |
| COPD | 5 | 4 | 1 |
| Asma | 3 | 2 | 1 |
| Vaping or smocking | 6 | 4 | 2 |
| BMI > 30 | 9 | 6 | 3 |
| Actual stageb | |||
| I | 1 | 1 | 0 |
| IIA | 2 | 2 | 0 |
| IIB | 3 | 2 | 1 |
| III | 6 | 4 | 2 |
| IVA | 18 | 13 | 5 |
| IVB | 55 | 28 | 27 |
| NED | 41 | 34 | 7 |
| Histological subtypeb | |||
| Type A | 3 | 3 | 0 |
| Type A-B | 8 | 8 | 0 |
| Type B1 | 8 | 8 | 0 |
| Type B2 | 21 | 21 | 0 |
| Type B3 | 23 | 23 | 0 |
| Thymic carcinoma | 41 | 0 | 41 |
| Other | 3 | 3 | 0 |
| Type B1/B2 | 4 | 4 | 0 |
| Type B2/B3 | 14 | 14 | 0 |
| Type B3/thymic carcinoma | 1 | 0 | 1 |
| Oncological treatment | |||
| Previous radiotherapy | 78 | 48 | 30 |
| Previous surgery on primary tumour | 95 | 71 | 24 |
| R0 | 73 | 55 | 18 |
| Not R0 | 22 | 16 | 6 |
| Received systemic treatmentc | 88 | 53 | 35 |
| Received systemic treatment within three months administration of vaccined | 36 | 19 | 17 |
Key: TET: thymic epithelial tumour; BPCO: chronic obstructive pulmonary disease; BMI: body mass index; NED: no evidence of disease.
a
Includes also type B3/thymic carcinoma.
b
Stage at the time of vaccination, according AJCC Cancer Staging, VIII ed
c
For any stage, independently from time of vaccination
d
Either before or after.